Interleukin-1: REGN began a U.S. placebo-controlled, double-blind Phase II trial of its IL-1 Trap in up to 200 patients with RA. The primary endpoint of the tri

Regeneron Pharmaceuticals Inc. (REGN), Tarrytown, N.Y. Product: Interleukin-1 (IL-1) Cytokine Trap Business: Autoimmune/Inflammation Therapeutic category: Immune suppression Target: IL-1 Description:...